2025
The impact of ionic excipients on stabilization of enalapril tablets by the formation of alkaline salt "in situ"
FRANC, Aleš; Bořek ŽALUDEK; Petr SOVA; Roman GONĚC; Jan MUSELÍK et al.Základní údaje
Originální název
The impact of ionic excipients on stabilization of enalapril tablets by the formation of alkaline salt "in situ"
Autoři
FRANC, Aleš; Bořek ŽALUDEK; Petr SOVA; Roman GONĚC a Jan MUSELÍK
Vydání
European Journal of Pharmaceutics and Biopharmaceutics, AMSTERDAM, Elsevier, 2025, 0939-6411
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.300 v roce 2024
Organizační jednotka
Farmaceutická fakulta
UT WoS
001521573800002
EID Scopus
2-s2.0-105009019492
Klíčová slova anglicky
Enalapril maleate; Tablets; Alkaline excipients; Sodium salt; Diacid; Diketopiperazine; Neutralization; Stability
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 7. 2025 10:37, Mgr. Irena Doubková
Anotace
V originále
The formation of salts is one of the possibilities of stabilizing medicinal substances. Salts can be prepared during the manufacture of the dosage form, saving time, reducing cost and environmental impact. Several studies have documented significant enalapril maleate (EM) instability. EM decomposes into diketopiperazine (DKP) and diacid (DA) impurities at elevated temperature and humidity. Notably, toxic DKP is preferentially formed at pH 2 - 3, and DA formation dominates at pH values above 5. This instability raises concerns about the therapeutic efficacy and safety of the drug. The proposed stabilization strategy involves the "in situ" conversion of EM into a stable sodium salt. This is achieved by incorporating suitable ionic excipients, specifically alkali metal salts and an ethanol-based hydrolysis inhibitor, into the granulation solution. This method effectively inhibits the deethylation to DA and provides uniform tablets with minimal DKP content to ensure long-term five-year stability. In general, these tablets show a lower content of degradation products compared to the stability results reported so far in various generics, and the amount of impurities meets the ICH Q3B (R2) requirements.